2023 World Conference on Lung Cancer (Posters)-P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data

P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data - PDF(Abstract)

Back to course

Pdf Summary

Determining the appropriate lines of therapy (LOT) in patients with metastatic non-small cell lung cancer (mNSCLC) is crucial for informing clinical decision-making and supporting clinical research. However, existing rules for determining LOT do not account for the increasing use of targeted therapies in treatment. This study aims to propose updated rules for determining LOT using real-world data from patients with mNSCLC treated with targeted therapies.<br /><br />The researchers defined a regimen as any systemic agent (chemotherapy, immunotherapy, or targeted therapy) or collection of agents administered together. The proposed rules aim to determine whether a change in regimen advances the LOT. The initial rules were applied to 550 patients with ALK-sensitizing alterations and mNSCLC, and then modified based on review by practicing thoracic oncologists. These modified rules were then applied to a cohort of 1133 patients with EGFR-sensitizing mutations and mNSCLC.<br /><br />The researchers proposed six rules for determining LOT in mNSCLC. If a change to a regimen meets Rules 1, 2, or 3, the LOT number remains the same. If these rules are not met, Rules 4-6 will advance the LOT. For example, if an angiogenesis inhibitor is added to a regimen within 90 days of the start of the prior regimen, the LOT stays the same. However, if the inhibitor is added more than 90 days after, the LOT advances.<br /><br />After applying the proposed rules, a total of 2834 LOTs were determined for the 1133 patients with EGFR mutations and mNSCLC. Rules 1-3 prevented 333 regimen changes from advancing the LOT.<br /><br />These proposed rules provide an updated framework for evaluating treatment patterns in patients with mNSCLC and accounting for the increased use of targeted therapies. The study aims to promote standardization of methods for determining LOT using real-world data.

Asset Subtitle

Melina Marmarelis

Meta Tag

Speaker Melina Marmarelis

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

lines of therapy

metastatic non-small cell lung cancer

mNSCLC

clinical decision-making

targeted therapies

regimen

ALK-sensitizing alterations

EGFR-sensitizing mutations

angiogenesis inhibitor

real-world data